13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

  
33 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03610139
(ClinicalTrials.gov)
May 21, 201813/7/2018Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis PatientsLongitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical TrialMultiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome;Clinically Isolated Syndrome, CNS Demyelinating;Vitamin D3 DeficiencyDietary Supplement: Vitamin D3American University of Beirut Medical CenterNULLRecruiting18 YearsN/AAll162N/ALebanon
2NCT02696590
(ClinicalTrials.gov)
July 201518/2/2016High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis PatientsIsfahan University of Medical SciencesRelapsing Remitting Multiple SclerosisDietary Supplement: Vitamin D3Isfahan University of Medical SciencesNULLCompleted23 Years59 YearsBoth200N/AIran, Islamic Republic of
3NCT02096133
(ClinicalTrials.gov)
October 13, 201421/3/2014Vitamin D3 and the Stress-axis in MSRegulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled StudyMultiple SclerosisDrug: Cholecalciferol;Other: Placebo comparatorAcademic MS Center LimburgNULLTerminated18 YearsN/AFemale54Phase 2Netherlands
4NCT01817166
(ClinicalTrials.gov)
July 16, 201320/3/2013Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated SyndromeMulticentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.Multiple SclerosisDrug: Vitamin D;Drug: Placebo;Other: Imaging;Biological: Lumbar puncture;Biological: Blood sampling;Biological: Urine samplesCentre Hospitalier Universitaire de NimesNULLActive, not recruiting18 Years56 YearsAll316Phase 3France
5EUCTR2012-004602-97-ES
(EUCTR)
11/01/201312/11/2012?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial??Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? - VITADEM RELAPSING-REMITING MULTIPLE SCLEROSIS
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: COLECALCIFEROL CONCENTRATE (OILY FORM)
Javier Olascoaga UrtazaNULLNot RecruitingFemale: yes
Male: yes
100Phase 2Spain
6NCT01753375
(ClinicalTrials.gov)
January 201317/12/2012Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple SclerosisRole of Vitamin D on the Relapse Rate of Multiple SclerosisMultiple SclerosisDietary Supplement: Vitamin D3;Dietary Supplement: PlaceboAlJohara M AlQuaiz, M.D.NULLNot yet recruiting18 Years55 YearsBoth200Phase 2Saudi Arabia
7NCT01728922
(ClinicalTrials.gov)
November 6, 20128/11/2012Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated SyndromeDose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.Clinically Isolated Syndrome;Multiple SclerosisDietary Supplement: 5000IU vitamin D;Dietary Supplement: 10000IU vitamin D;Other: PlaceboUniversity College DublinUniversity of Dublin, Trinity College;St Vincent's University Hospital, IrelandCompleted18 Years55 YearsAll64Phase 1/Phase 2Ireland
8NCT01490502
(ClinicalTrials.gov)
March 20126/12/2011Vitamin D Supplementation in Multiple SclerosisA Randomized Controlled Trial of Vitamin D Supplementation in Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: Vitamin D3Johns Hopkins UniversityOregon Health and Science University;University of California, San Francisco;Washington University School of Medicine;Icahn School of Medicine at Mount Sinai;University of Pennsylvania;Yale University;The Cleveland Clinic;University of Rochester;Stanford University;University of Virginia;Swedish Medical Center;Anne Arundel Health System Research Institute;Columbia University;University of Massachusetts, Worcester;Dignity HealthCompleted18 Years50 YearsAll172Phase 3United States
9EUCTR2010-020328-23-PT
(EUCTR)
06/01/201217/11/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA - Geneva, an affiliate of Merck KGaA,NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Hungary;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
10EUCTR2010-020328-23-AT
(EUCTR)
23/11/201128/10/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA - Geneva, an affiliate of Merck KGaA,NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Hungary;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
11EUCTR2011-002785-20-DE
(EUCTR)
19/09/201111/08/2011Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple SclerosisEfficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis - EVIDIMS Multiple Sclerosis and Clinical isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Vigantol® Öl 20.000 I.E./ml
Product Name: Vigantol® Öl 20.000 I.E./ml
Product Code: Vigantol® Öl 20.000 I.E./ml
INN or Proposed INN: COLECALCIFEROL
Trade Name: Dekristol®-Tablette 1 (400 IE)
Product Name: Dekristol® 400-Tabletten
Product Code: Dekristol® 400-Tabletten
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: 25OH-Vitamin D
Charité - Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany
12EUCTR2010-020328-23-LV
(EUCTR)
19/07/201116/05/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 16.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Latvia;Norway;Germany;Netherlands
13EUCTR2010-020328-23-LT
(EUCTR)
09/05/201102/03/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oil
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
14EUCTR2010-020328-23-EE
(EUCTR)
26/04/201121/03/2011Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
15EUCTR2010-020328-23-BE
(EUCTR)
01/04/201118/11/2010A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARA three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono SA-Geneva an affiliate of Merck KgaA, DarmstadtNULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Belgium;Lithuania;Austria;Denmark;Latvia;Germany;Netherlands;Italy
16EUCTR2010-023677-19-IT
(EUCTR)
23/03/201110/06/2011Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 PATIENT WITH RRMS AND SPMS
MedDRA version: 13.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 10029205 - Nervous system disorders
Trade Name: BETAFERON*15CONFEZ 0,25MG/ML+
INN or Proposed INN: Interferon beta-1b
Trade Name: EXTAVIA*SC 15FL 250MCG/ML+15SI
INN or Proposed INN: Interferon beta-1b
Trade Name: DIBASE
INN or Proposed INN: Colecalciferol
AZIENDA OSPEDALIERA S. LUIGI GONZAGANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
17EUCTR2010-020328-23-IT
(EUCTR)
10/03/201107/02/2011A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH REBIF (SOLAR) - SOLARA THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH REBIF (SOLAR) - SOLAR RELAPSING REMITTING MULTIPLE SCLEROSIS
MedDRA version: 9.1;Level: PT;Classification code 10063399
Trade Name: VIGANTOL OIL
INN or Proposed INN: Colecalciferol
MERCK SERONO SANULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Belgium;Lithuania;Austria;Denmark;Latvia;Germany;Netherlands;Italy
18EUCTR2010-020328-23-DE
(EUCTR)
31/01/201127/10/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: CHOLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Italy;Switzerland;Belgium;Denmark;Germany;Latvia;Netherlands;Norway
19EUCTR2010-020328-23-NL
(EUCTR)
06/01/201116/09/2010A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLARA three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck Serono The Netherlands - a division of Merck B.V.NULLNot RecruitingFemale: yes
Male: yes
358Phase 2Portugal;Estonia;Finland;Belgium;Lithuania;Austria;Denmark;Latvia;Germany;Netherlands;Italy
20EUCTR2010-020328-23-DK
(EUCTR)
09/12/201008/11/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
21NCT01667796
(ClinicalTrials.gov)
November 201013/8/2012Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthPharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy ControlsMultiple Sclerosis, Relapsing-remittingDietary Supplement: Vitamin D3Johns Hopkins UniversityUniversity of California, San Francisco;National Multiple Sclerosis SocietyCompleted18 Years60 YearsFemale57N/AUnited States
22EUCTR2010-020328-23-FI
(EUCTR)
21/10/201027/08/2010Supplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment.A three-arm, randomized, double-blind, placebo controlled, multicenter,phase II study to evaluate the efficacy of Vigantol® oil as add-ontherapy in subjects with Relapsing-Remitting Multiple Sclerosis receivingtreatment with 44 µg tiw of Rebif®SOLARSupplementation of VigantOL® Oil versus Placebo as Add-on in Patientswith Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR Relapsing-Remitting Multiple Sclerosis
MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol Oel
Product Name: Vigantol Oil
Product Code: 200106 or EMD 28162
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: Cholecalciferol, Vitamin D3
Merck SeronoNULLNot RecruitingFemale: yes
Male: yes
230Phase 2Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
23NCT01005095
(ClinicalTrials.gov)
October 201029/10/2009The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis PatientsA One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple SclerosisMULTIPLE SCLEROSISDietary Supplement: Vitamin D3Carmel Medical CenterNULLTerminated18 Years65 YearsBoth45Phase 4Israel
24NCT01024777
(ClinicalTrials.gov)
March 20102/12/2009Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple SclerosisA Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple SclerosisMultiple Sclerosis;Vitamin D DeficiencyDrug: CholecalciferolJohns Hopkins UniversityNULLCompleted18 Years55 YearsBoth40Phase 1United States
25NCT01198132
(ClinicalTrials.gov)
November 20098/9/2010A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyA Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyMultiple SclerosisDietary Supplement: Cholecalciferol (Vitamin D3);Dietary Supplement: Placebo;Drug: RebifMerck KGaAMerck Serono S.A.S, FranceCompleted18 Years65 YearsAll129Phase 2France
26EUCTR2009-013695-46-FR
(EUCTR)
22/10/200907/09/2009ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - cholineETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline Sclérose en plaques récurrente (SEP-R)
MedDRA version: 12.0;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: UVEDOSE 100 000 UI, solution buvable en ampoule
Product Name: UVEDOSE 100 000 UI
INN or Proposed INN: COLECALCIFEROL
MERCK SERONO s.a.sNULLNot RecruitingFemale: yes
Male: yes
France
27NCT00940719
(ClinicalTrials.gov)
August 200915/7/2009Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot StudyMultiple SclerosisDietary Supplement: vitamin D3Maastricht University Medical CenterOrbis Medical CentreCompleted18 YearsN/ABoth15N/ANetherlands
28NCT01339676
(ClinicalTrials.gov)
March 200819/4/2011Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MSMultiple SclerosisDrug: Colecalciferol;Drug: Placebo capsulesUniversity of TurkuNULLActive, not recruiting18 Years55 YearsBoth70Phase 4Finland
29NCT01432704
(ClinicalTrials.gov)
March 200816/8/2011Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Phase IV Study of Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MSMultiple SclerosisDrug: colecalciferolUniversity of TurkuBayerCompleted18 Years50 YearsBoth70Phase 2/Phase 3NULL
30NCT00785473
(ClinicalTrials.gov)
January 20084/11/2008Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple SclerosisCan Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre StudyMultiple Sclerosis, OsteoporosisDietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonateUniversity Hospital of North NorwayNULLCompleted18 Years50 YearsBoth80Phase 4Norway
31EUCTR2007-001958-99-FI
(EUCTR)
18/12/200707/12/2007Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MSCollecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS Patients with relapsing remitting MS according to the revised Mc Donald's criteria who meet all criteria for inclusion and none criteria of exclusion.
MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
Trade Name: Dekristol 20000 IE
Product Name: Dekristol
INN or Proposed INN: INN COLECALCIFEROL
Product Name: Placebo Dekristol SGC 20000
Merja Soilu HäninenNULLNot RecruitingFemale: yes
Male: yes
Finland
32NCT00644904
(ClinicalTrials.gov)
July 200624/3/2008Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple SclerosisA Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple SclerosisMultiple SclerosisDietary Supplement: Vitamin D3University of TorontoDirect MS-Proactive Charity;Multiple Sclerosis Society of CanadaCompleted18 Years55 YearsBoth49Phase 1/Phase 2Canada
33EUCTR2014-000728-97-NL
(EUCTR)
08/05/2014Regulation of the stress-axis by vitamin D in subjects with multiple sclerosis.Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study - Vitamin D3 and the stress-axis in MS Relapsing remitting multiple sclerosis
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigantol® Oil
Product Name: Vigantol® Oil
Product Code: EMD 28162
Academic MS Center LimburgNULLNot RecruitingFemale: yes
Male: no
Phase 2Netherlands